Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383872016> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4383872016 endingPage "86" @default.
- W4383872016 startingPage "81" @default.
- W4383872016 abstract "The advent of targeted therapies and immunotherapies has revolutionized metastatic melanoma (MM) management but their use is associated with high daily costs compared to chemotherapies: €2 for dacarbazine versus €175 for immunotherapies and €413 for targeted therapies. While overall survival (OS) has increased, healthcare expenditures are expected to double by 2030.The aim of this study was to estimate the median OS and costs for MM patients in order to evaluate the effectiveness of new biological or targeted therapies (NT) used since 2013 compared to chemotherapies.This was a retrospective monocentric cost-effectiveness analysis performed in CHU Nantes (Nantes University Hospital). All MM patients treated with conventional chemotherapy as first-line treatment between 2008 and 2012 were included (CHEMO group). The same number of patients treated with NT as first-line between 2013 and 2017 were included (NT group).In total, 161 patients were included in each group. The mean age at diagnosis was 64.7±2.4 years in the CHEMO group and 65.3±2.4 years in the NT group (not significant). The men/women ratio was 1.48 and 1.27, respectively, (not significant). The median OS was 158 days in the CHEMO group and 395 days in the NT group (p<0.001). Treatment cost was €10,280/patient versus €94,676/patient, respectively. The mean incremental cost-effectiveness ratio was €90,184/LY (95% CI: €59,637; €166,395).Our study assessed clinical and economic features associated with MM management before and after the advent of NT. Costs and life expectancy have increased. NT appears to be cost-effective." @default.
- W4383872016 created "2023-07-12" @default.
- W4383872016 creator A5001247907 @default.
- W4383872016 creator A5002644565 @default.
- W4383872016 creator A5004989332 @default.
- W4383872016 creator A5009908507 @default.
- W4383872016 creator A5014299149 @default.
- W4383872016 creator A5024239310 @default.
- W4383872016 creator A5035899929 @default.
- W4383872016 creator A5037929314 @default.
- W4383872016 creator A5045260573 @default.
- W4383872016 creator A5046705863 @default.
- W4383872016 creator A5086415212 @default.
- W4383872016 date "2023-04-01" @default.
- W4383872016 modified "2023-10-17" @default.
- W4383872016 title "Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma" @default.
- W4383872016 doi "https://doi.org/10.1684/ejd.2023.4448" @default.
- W4383872016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37431110" @default.
- W4383872016 hasPublicationYear "2023" @default.
- W4383872016 type Work @default.
- W4383872016 citedByCount "0" @default.
- W4383872016 crossrefType "journal-article" @default.
- W4383872016 hasAuthorship W4383872016A5001247907 @default.
- W4383872016 hasAuthorship W4383872016A5002644565 @default.
- W4383872016 hasAuthorship W4383872016A5004989332 @default.
- W4383872016 hasAuthorship W4383872016A5009908507 @default.
- W4383872016 hasAuthorship W4383872016A5014299149 @default.
- W4383872016 hasAuthorship W4383872016A5024239310 @default.
- W4383872016 hasAuthorship W4383872016A5035899929 @default.
- W4383872016 hasAuthorship W4383872016A5037929314 @default.
- W4383872016 hasAuthorship W4383872016A5045260573 @default.
- W4383872016 hasAuthorship W4383872016A5046705863 @default.
- W4383872016 hasAuthorship W4383872016A5086415212 @default.
- W4383872016 hasConcept C112930515 @default.
- W4383872016 hasConcept C126322002 @default.
- W4383872016 hasConcept C141071460 @default.
- W4383872016 hasConcept C143998085 @default.
- W4383872016 hasConcept C2776694085 @default.
- W4383872016 hasConcept C2777658100 @default.
- W4383872016 hasConcept C2780964509 @default.
- W4383872016 hasConcept C3019080777 @default.
- W4383872016 hasConcept C502942594 @default.
- W4383872016 hasConcept C71924100 @default.
- W4383872016 hasConceptScore W4383872016C112930515 @default.
- W4383872016 hasConceptScore W4383872016C126322002 @default.
- W4383872016 hasConceptScore W4383872016C141071460 @default.
- W4383872016 hasConceptScore W4383872016C143998085 @default.
- W4383872016 hasConceptScore W4383872016C2776694085 @default.
- W4383872016 hasConceptScore W4383872016C2777658100 @default.
- W4383872016 hasConceptScore W4383872016C2780964509 @default.
- W4383872016 hasConceptScore W4383872016C3019080777 @default.
- W4383872016 hasConceptScore W4383872016C502942594 @default.
- W4383872016 hasConceptScore W4383872016C71924100 @default.
- W4383872016 hasIssue "2" @default.
- W4383872016 hasLocation W43838720161 @default.
- W4383872016 hasLocation W43838720162 @default.
- W4383872016 hasOpenAccess W4383872016 @default.
- W4383872016 hasPrimaryLocation W43838720161 @default.
- W4383872016 hasRelatedWork W1992414795 @default.
- W4383872016 hasRelatedWork W2001693787 @default.
- W4383872016 hasRelatedWork W2028567029 @default.
- W4383872016 hasRelatedWork W2047967234 @default.
- W4383872016 hasRelatedWork W2084640577 @default.
- W4383872016 hasRelatedWork W2254812154 @default.
- W4383872016 hasRelatedWork W2289813745 @default.
- W4383872016 hasRelatedWork W2397644467 @default.
- W4383872016 hasRelatedWork W2399057994 @default.
- W4383872016 hasRelatedWork W2439875401 @default.
- W4383872016 hasVolume "33" @default.
- W4383872016 isParatext "false" @default.
- W4383872016 isRetracted "false" @default.
- W4383872016 workType "article" @default.